LAUSR

Simple Summary Oligodendroglioma is an uncommon brain tumor that often affects younger and middle-aged adults and can progress slowly over many years. The current treatment approach relies on surgery followed by radiation and a three-drug chemotherapy regimen known to improve long-term survival, although many patients struggle with significant treatment-related side effects. Recently, new medicines have been developed that directly target the genetic changes that drive these tumors. These targeted treatments are generally easier to tolerate and may postpone the need for radiation or chemotherapy, but they have not yet been compared directly with the long-established regimen. In this review, we gathered and evaluated all available studies on both approaches to clarify what is known about their benefits, their risks, and the strength of evidence supporting each option. We found that the traditional regimen remains the only therapy with proven survival advantages measured over many years, while the targeted medicines offer early signs of disease control with fewer severe side effects. These findings highlight the need for future studies that directly compare the two strategies. They also provide patients and clinicians with a clearer foundation for thoughtful, individualized treatment decisions.